SCHEMBL264380

SCHEMBL264380

Cc1cc(N(CCc2ccc(C(F)(F)F)cc2)C(=O)[C@@H](O)c2ccccc2)ccn1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 7/20 0.43
SLC6A9 P48067 1/20 0.37
PSEN1 P49768 1/20 0.37
PSEN2 P49810 1/20 0.37
APH1B Q8WW43 1/20 0.37
NCSTN Q92542 1/20 0.37
APH1A Q96BI3 1/20 0.37
PSENEN Q9NZ42 1/20 0.37
MAPK14 Q16539 2/20 0.37
NR3C2 P08235 1/20 0.37
MCHR1 Q99705 1/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
GPR55 Q9Y2T6 1/20 0.37
UTS2R Q9UKP6 1/20 0.36
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
SORT1 Q99523 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL264378 1.00 TACR1 (0.43) TACR1SLC6A9PSEN1PSEN2APH1B
SCHEMBL264379 1.00 TACR1 (0.43) TACR1SLC6A9PSEN1PSEN2APH1B
SCHEMBL265316 0.85 TACR1 (0.41) TACR1SLC6A9MCHR1KMT2AMEN1
SCHEMBL265317 0.85 TACR1 (0.41) TACR1SLC6A9MCHR1KMT2AMEN1
SCHEMBL265315 0.85 TACR1 (0.41) TACR1SLC6A9MCHR1KMT2AMEN1
SCHEMBL3647441 0.85 TACR1 (0.45) TACR1SLC6A9MCHR1KMT2AMEN1
SCHEMBL3647153 0.85 TACR1 (0.45) TACR1SLC6A9MCHR1KMT2AMEN1
SCHEMBL3647156 0.85 TACR1 (0.45) TACR1SLC6A9MCHR1KMT2AMEN1
SCHEMBL264390 0.83 PDPK1 (0.41) TACR1MAPK14NR3C2MCHR1KMT2A
SCHEMBL265100 0.83 TRPM8 (0.41) TACR1SLC6A9MCHR1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133909-B2 Heteroaromatic monoamides as orexinin receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
CN-102066325-A Heteroaromatic monoamides as orexin receptor antagonists HOFFMANN LA ROCHE 2011-05-18 CN disclosed
EP-2297102-A1 HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2011-03-23 EP disclosed
WO-2009153180-A1 HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-12-23 WO disclosed
US-20090312314-A1 HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312314-A1 HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPSR1 TACR1 60/4885SLC6A9 4467/4885PSEN1 647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.